A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study with a Long-Term OpenLabel Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients with Hemophilic Arthropathy